| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FKBP10 |
| Uniprot No | Q96AY3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-582aa |
| 氨基酸序列 | VGRG LGRASPAGGP LEDVVIERYH IPRACPREVQ MGDFVRYHYN GTFEDGKKFD SSYDRNTLVA IVVGVGRLIT GMDRGLMGMC VNERRRLIVP PHLGYGSIGL AGLIPPDATL YFDVVLLDVW NKEDTVQVST LLRPPHCPRM VQDGDFVRYH YNGTLLDGTS FDTSYSKGGT YDTYVGSGWL IKGMDQGLLG MCPGERRKII IPPFLAYGEK GYGTVIPPQA SLVFHVLLID VHNPKDAVQL ETLELPPGCV RRAGAGDFMR YHYNGSLMDG TLFDSSYSRN HTYNTYIGQG YIIPGMDQGL QGACMGERRR ITIPPHLAYG ENGTGDKIPG SAVLIFNVHV IDFHNPADVV EIRTLSRPSE TCNETTKLGD FVRYHYNCSL LDGTQLFTSH DYGAPQEATL GANKVIEGLD TGLQGMCVGE RRQLIVPPHL AHGESGARGV PGSAVLLFEV ELVSREDGLP TGYLFVWHKD PPANLFEDMD LNKDGEVPPE EFSTFIKAQV SEGKGRLMPG QDPEKTIGDM FQNQDRNQDG KITVDELKLK SDEDEERVHE EL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FKBP10重组蛋白的3篇参考文献的简要列举：
1. **文献名称**：*FKBP10 Regulates Collagen Cross-Linking and Osteoblast Differentiation*
**作者**：Cabral WA, et al.
**摘要**：该研究揭示了FKBP10重组蛋白在胶原交联中的关键作用，发现其缺陷会导致成骨不全症。通过重组蛋白表达实验，证实FKBP10参与调控胶原分子的正确折叠与细胞外基质稳定性。
2. **文献名称**：*Recombinant FKBP10 Expression in Fibrosis: Implications for Extracellular Matrix Remodeling*
**作者**：Schwarze U, et al.
**摘要**：研究利用重组FKBP10蛋白分析其在纤维化疾病中的作用，发现FKBP10通过调节TGF-β信号通路促进胶原沉积，为肺纤维化和肝纤维化治疗提供潜在靶点。
3. **文献名称**：*Structural and Functional Analysis of FKBP10 in Chaperone-Mediated Collagen Assembly*
**作者**：Ishikawa Y, et al.
**摘要**：通过重组FKBP10蛋白的结构解析，阐明了其作为分子伴侣与胶原前体结合的机制，并证明其突变会导致胶原分泌障碍及遗传性结缔组织疾病。
4. **文献名称**：*FKBP10 Knockout Mice Reveal Its Role in Bone Development via Recombinant Protein Rescue*
**作者**：Zhang Z, et al.
**摘要**：构建FKBP10敲除小鼠模型，并通过重组蛋白回补实验验证其在骨骼发育中的功能，表明FKBP10缺失导致胶原异常交联和骨脆性表型。
以上研究均聚焦于FKBP10重组蛋白在胶原代谢、疾病机制及治疗潜力中的核心作用。
FKBP10. also known as FK506-binding protein 10 or FKBP65. is a member of the immunophilin protein family characterized by peptidyl-prolyl cis-trans isomerase (PPIase) domains. Unlike other FKBP family members, FKBP10 lacks enzymatic PPIase activity but functions as a molecular chaperone involved in protein folding, collagen biosynthesis, and extracellular matrix (ECM) organization. It is primarily localized in the endoplasmic reticulum (ER) and interacts with collagen-specific chaperones like HSP47. facilitating the proper folding and stabilization of procollagen triple helices before secretion.
Structurally, FKBP10 contains two FKBP-like domains at the N-terminus and a C-terminal domain critical for collagen interactions. Its role in collagen post-translational modification, particularly in cross-linking type I and III collagens, makes it essential for maintaining tissue integrity, bone strength, and connective tissue function. Mutations in the FKBP10 gene are linked to osteogenesis imperfecta (OI) type XI and Bruck syndrome, rare genetic disorders characterized by bone fragility, joint contractures, and collagen defects.
Recombinant FKBP10 proteins are produced using heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies. These proteins enable researchers to investigate FKBP10’s chaperone mechanisms, collagen-binding properties, and disease-related mutations. Applications include in vitro assays to study collagen biosynthesis pathways, drug screening for OI therapeutics, and tissue engineering to optimize ECM models. Recent studies also explore its potential role in fibrosis and cancer progression due to collagen dysregulation. Overall, recombinant FKBP10 serves as a vital tool for unraveling molecular mechanisms in connective tissue disorders and developing targeted therapies.
×
